Loading stock data…
CRMD
$7.66-0.26 (-3.28%)
Market ClosedLast close May 11
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CorMedix Inc. in the Healthcare sector is trading at $7.66. The stock is currently near its 52-week low of $6.13, remaining 21.4% below its 200-day moving average. Technical signals show neutral RSI of 56 and bullish MACD crossover, explaining why CRMD maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.66
Potential Upside
609.4%
Whystock Fair Value$54.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$592.09M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.67
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
40.23%
Volume
Today's trading volume
1.09M
Recent News
How The CorMedix (CRMD) Story Is Shifting As Analysts Split On US$13–US$15 Targets
CorMedix is back in focus as analysts refresh their models, with price targets now clustering around US$13 on the cautious side and US$15 at the top end. That spread reflects a debate over how recent developments line up with earlier expectations, and whether the higher US$15.00 target still fits the current story. Read on to see what is driving the split view and how to keep track of this evolving analyst narrative around the stock. Analyst Price Targets don't always capture the full story...
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
The Joint (JYNT) delivered earnings and revenue surprises of +166.67% and +5.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix Outlines Post-Melinta Growth, Q2 REZZAYO Phase 3 Catalyst and DefenCath Reimbursement Shift
CorMedix (NASDAQ:CRMD) Chief Executive Officer Joe Todisco outlined the company’s evolving strategy and upcoming catalysts during a fireside chat at Needham & Company’s 25th Annual Healthcare Conference, emphasizing recent portfolio expansion, an approaching Phase 3 data readout for REZZAYO, and
How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets
CorMedix is back in focus as price targets across the Street shift, with some firms cutting their views by roughly $5 to $9 even as others keep targets in the mid teens and maintain positive ratings. These changes are tied directly to the company’s 2026 and 2027 revenue guidance, which sits about 40% below prior models and includes a much lower outlook for DefenCath, dividing opinion on long term execution and earnings power. As you read on, you will see what is driving this split and how to...